IDRSF News and Press, Idorsia AG From 04/26/23

2023-04-26 11:35:44 ET Summary Idorsia missed top-line sales estimates. Only a quarter of liquidity, there was no funding news, and this increased the risk of equity dilution. Idorsia confirmed its 2025 financial targets but is lagging behind 2023 sales. Idorsia ( ...

2023-04-25 13:07:10 ET Idorsia Ltd (IDRSF) Q1 2023 Earnings Conference Call April 25, 2023 07:00 AM ET Company Participants Andrew Weiss - Head of Investor Relations Jean-Paul Clozel - Chief Executive Officer Simon Jose - Executive Vice President and Chief Commer...

2023-04-25 12:31:07 ET The following slide deck was published by Idorsia Ltd in conjunction with their 2023 Q1 earnings call. For further details see: Idorsia Ltd 2023 Q1 - Results - Earnings Call Presentation

Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep 1-3 ; research on wider societal and indirect economic costs associated with CID have been limited to date 1 New report indicates annual lost productivity c...

Summary Idorsia reported the yearly results for 2022 with some very positive developments, while also discussing important risk factors. Clazosentan will not see the US and the EU market but could be allowed in other Asian countries. QUVIVIQ continues to penetrate the commercial mar...

Summary 2023 could be a key year in Idorsia's revenue trajectory. We are forecasting more launches across the European region. Insomnia Market is expected to reach a market value of over USD 8 billion by 2026. Idorsia needs to deliver and is already gaining market share vs comps. Id...

Idorsia Ltd (IDRSF) Q4 2022 Earnings Conference Call February 7, 2023 08:00 a.m. ET Company Representatives Jean-Paul Clozel - Chief Executive Officer André Muller - Chief Financial Officer Simon Jose - Chief Commercial Officer Andrew Weiss - Head of IR ...

Idorsia press release ( OTCPK:IDRSF ): FY GAAP EPS of -CHF4.67. Revenue of CHF97M (+177.1% Y/Y). For further details see: Idorsia GAAP EPS of -CHF4.67, revenue of CHF97M

The following slide deck was published by Idorsia Ltd in conjunction with their 2022 Q4 earnings call. For further details see: Idorsia Ltd 2022 Q4 - Results - Earnings Call Presentation

Summary Idorsia is a Swiss biopharmaceutical company with multiple commercial and pre-commercial assets. Idorisa's lead asset Daridorexant seems to be a more attractive option compared to SOC in Isomnia due to lower a) drug abuse, b) withdrawal symptoms, and c) rebound insomnia. The...